The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy

Angiogenesis

Volumn 18, Issue 1, 2015, Pages 23-30

  Carter, James G ^a,b   Gammons, Melissa V R ^a   Damodaran, Gopinath ^a   Churchill, Amanda J ^a   Harper, Steven J ^a   Bates, David O ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bevacizumab; Splicing; VEGF; VEGF A165b

Indexed keywords

BEVACIZUMAB; EXON8A POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN A ANTIBODY; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; ANTIBODY; ISOPROTEIN;

AGE RELATED MACULAR DEGENERATION; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN MOTIF; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID MOTIFS; ANGIOGENESIS INHIBITORS; ANTIBODIES; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921935949     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-014-9444-3     Document Type: Article

References (25)

1. Artac RA, McFee RM, Smith RAL, Baltes-Breitwisch MM, Clopton DT, Cupp AS (2009) Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary. Biol Reprod 81(5):978–988
2. Bates DO, Catalano PJ, Symonds KE, Varey AHR, Ramani P, O’Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ (2012) Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 18(22):6384–6391
3. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ (2002) VEGF(165)b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62(14):4123–4131
4. Bates DO, MacMillan PP, Manjaly JG, Qiu Y, Hudson SJ, Bevan HS, Hunter AJ, Soothill PW, Read M, Donaldson LF, Harper SJ (2006) The endogenous anti-angiogenic family of splice variants of VEGF, VEGF(xxx)b, are down-regulated in pre-eclamptic placentae at term. Clin Sci 110(5):575–585
5. Bhattacharjee G, Asplin IR, Wu SM, Gawdi G, Pizzo SV (2000) The conformation-dependent interaction of alpha(2)-macroglobulin with vascular endothelial growth factor—a novel mechanism of alpha(2)-macroglobulin/growth factor binding. J Biol Chem 275(35):26806–26811
6. Bills VL, Varet J, Millar A, Harper SJ, Soothill PW, Bates DO (2009) Failure to up-regulate VEGF(165)b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci 116(3–4):265–272
7. 165b on invasion and migration of human lung adenocarcinoma A549 cells. J Huazhong Univ Sci Technol Med Sci 31(5):619–624
8. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4–25
9. Hurwitz H (2004) Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4(suppl 2):S62–S68
10. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L (2008) Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 68(12):4683–4692
11. Mitchell P (2011) A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 27(7):1465–1475
12. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci 94(14):7192–7197
13. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO (2010) Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms—a novel therapeutic strategy for angiogenesis. J Biol Chem 285(8):5532–5540
14. Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I, Miyake M, Yoshimura N (2013) Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefe’s Arch Clin Exp Ophthalmol 251(1):1–7
15. Parker MW, Xu P, Li X, Vander Kooi CW (2012) Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 287(14):11082–11089. doi:10.1074/jbc.M111.331140
16. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ (2005) Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48(11):2422–2427
17. Plouet J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F (1997) Extracellular cleavage of the vascular endothelial growth factor 189- amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 272(20):13390–13396
18. Pritchard-Jones RO, Dunn DBA, Qiu Y, Varey AHR, Orlando A, Rigby H, Harper SJ, Bates DO (2007) Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 97(2):223–230
19. Qiu Y, Bevan H, Weeraperuma S, Wratting D, Murphy D, Neal CR, Bates DO, Harper SJ (2008) Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF(165)b. FASEB J 22(4):1104–1112
20. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schuler Y, Kelly SP, Finucane C, Ellison D, Cebe-Suarez S, Ballmer-Hofer K, Mather S, Stewart L, Bates DO, Harper SJ (2008) Recombinant human VEGF(165)b protein is an effective anti-cancer agent in mice. Eur J Cancer 44(13):1883–1894
21. Rennel ES, Waine E, Guan H, Schuler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman ES, Bates DO, Harper SJ (2008) The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice. Br J Cancer 98(7):1250–1257
22. Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46(11):5629–5632
23. Suarez SC, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, Manlius C, Wood J, Ballmer-Hofer K (2006) A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 63(17):2067–2077
24. Varey AHR, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB, Harper SJ, Bates DO (2008) VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 98(8):1366–1379
25. Woolard J, Wang W, Bevan H, Qiu Y, Morbidelli L, Pritchard-Jones R, Cui T, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields J, Whittles C, Mushens R, Gillatt D, Ziche M, Harper S, Bates D (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64(21):7822–7835